Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsIra M. Jacobson, David R. Nelson, William T. Symonds et al.|New England Journal of Medicine|2013Cited by 1.1k
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinJordan J. Feld, Barry Bernstein, Kris V. Kowdley et al.|New England Journal of Medicine|2014Cited by 907
Residual NADPH Oxidase and Survival in Chronic Granulomatous DiseaseDouglas B. Kuhns, John I. Gallin, W. Gregory Alvord et al.|New England Journal of Medicine|2010Cited by 560
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology CommissionGraham Cooke, Alexandre de Araújo, Isabelle Andrieux‐Meyer et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 539
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradicationHarry L.A. Janssen, Jordan J. Feld, Harald Hofer et al.|Journal of Hepatology|2016Cited by 273